INTRODUCTION
Various human cancers show family history as a risk of the same cancer developing in related family members. are associated with lobular parenchymal atrophy and chronic pancreatitis-like changes observable by endoscopic ultrasonography (EUS). 32 Despite the difference in these precursor lesions, 30 ,32 a blind histological observation of 519 FPCs and 561 SPCs by expert pathologists did not show significant difference in terms of tumor size, location, neural invasion, angiolymphatic invasion, lymph nodal metastasis, and pathological stage. 34 The genomewide allelic status, 35, 36 and genetic (K-ras, TP53, and DPC4) and epigenetic (CDKN2A, NPTX2, ppENK, SPARC, etc.) alterations frequently observed in PCs 37 were also similar between SPC and FPC.
Genetics (germline)
However, in a small proportion (<20%) of FPC, deleterious germline mutation of the genes functioning in the homologous recombination (HR) pathway has been reported from the Western countries; ATM (mutation rate: 2% to 4%), 38 BRCA1
(0% to 7%), 39, 40 BRCA2 (4% to 17%), 16, 41 CHEK2 (1% to 6%), 42 PALB2 (1% to 3%), 43, 44 and RAD51 (4%). In Asian countries, Takai et al. 45 reported the similar mutation pattern in Japanese FPC cases (mutated in eight [15%] of 54 analyzed FPC cases: BRCA2, three; PALB2, two; ATM, two; and MLH1, one). In Korea, although germline BRCA1/2 mutation was recognized in 22% of the breast cancer patients with a family history of breast and ovarian cancers, 46 null pathogenic BRCA2 mutation was detected in 60 PC patients. 47 Even other than BRCA, defects of these genes cause dysfunction of the double strand DNA repair system (BRCAness).
48
BRCA1/2 mutation carriers have a mild to moderate level of risk for PC (RRs, 2 to 8; lifetime risks, 2% to 17%), but some specific mutation types may have further increased risks. For instance, BRCA2 6174delT, which is a Jewish founder mutation, was detected in 13% (3/23) of Jewish PC cases (odds for having PC, 12.8). 49 The BRCA2 K3326X mutation was detected in 5.6% (5/144) of American FPC cases, significantly more frequently than in SPCs. 50 A murine model confirmed that a germline BRCA2 mutation suffices to promote carcinogenesis by the KRAS mutation, 51 which is recognized in nearly 90% of PC cases, 52 explaining the function of BRCA2 mutation in FPC.
CLINICAL MANAGEMENT OF FPC 1. Familial pancreatic cancer registry
The FPC registry system began from the establishment of The National Familial Pancreas Tumor Registry (http://pathology. jhu.edu/pancreas/nfptr/history.php) (1994) at Johns Hopkins University (Baltimore, MD, USA). 53 This was followed by the Eu- 
Surveillance of high-risk individuals
Consortiums and symposiums have also been organized among several high volume centers and/or FPC registries across the globe, such as International Symposium on Inherited Diseases of the Pancreas (1997~) 57 and International Cancer of the Pancreas Screening Consortium (CAPS) (2011~). 58 Their aims have been to gather information on patients and families of PC and to study the cause of FPC, with the ultimate goal of improving the clinical practice of counseling and screening of the HRIs, and to devise early detection methods for PC and better treatments.
1) Targeted pathological lesions
The CAPS consortium summit held in Baltimore (2011) concluded that the success of a screening program for HRIs is defined as the detection and treatment of high-grade precursors IPMN, 59 pancreatic cyst, 68 pancreatic duct ectasia, 68 and so forth.
For instance, a patient with diabetes mellitus and a smoking history and a patient with one FDR with PC each showed a 10-fold risk when compared with negative controls. 8 Therefore, the initial counseling should be used to present modifiable risks related to the lifestyle to HRIs and their improvement should be recommended; that is, smoking cessation, a healthy diet high in fruits and vegetables (vitamin), and regular exercise to control weight (body mass index <25 kg/m 2 ). 57 
3) Modalities of screening
Although not reaching complete consensus in the CAPS meeting, 58 EUS is though as the most suitable modality, based on its ability to detect small pancreatic lesions (<1 cm). 69, 70 EUS is also superior at detecting risk findings frequently seen in HRIs, such as duct ectasia, cysts, 68 and parenchymal findings of the pancreas. 32 However, agreement is poor in terms of these characteristic findings, even among expert endosonographers. 4) Timing to start screening and screening interval Screening in many institutions is started at 40 years of age 69, 75 or 10 years younger than the age of the youngest relative with PC. 27, 74 As PC develops in cases of Peutz-Jeghers syndrome at a young age (40.8 years), 11 screening is started at 30 years old. 69 However, detection of pancreatic lesions increases after age 50 to 60 years old. 73 No consensus has been reached regarding the age to initiate screening and more than half (51%) of the experts in CAPS consortium voted the initial screening at age 50 years old. 58 Many institutions opt for yearly screening if the latest EUS and/or computed tomography is normal. 58 Once an abnormal finding is observed, subsequent screening is done every 3 to 6 months 28,69,76 or 3 to 12 months. 58 The endorsed screening interval for a non-suspicious cyst is 6 to 12 months, 3 months for a newly detected solid lesion if surgery is not imminent, and 3 months for an indeterminate main pancreatic duct stricture. The natural history and progression of FPC still require study to determine the appropriate duration for screening intervals in relation to the risk level.
5) Surgical indications and procedures
The extent of resection is controversial, depending on the therapeutic concept. The choices are to remove all precancerous lesions 74 or to resect only a targeted area that includes nodular or cystic lesions. 69 In cases of HBOC with the BRCA mutation, risk-reducing salpingo-oophorectomy is affordable and has an acceptable level of complications. 77 However, for the pancreas, total pancreatectomy (TP) has severe complications, including a considerable level of postsurgical in-hospital mortality (5% to 23% in Germany) 78, 79 and subsequent serious glycemic control failure (mortality, 4% to 8% per year). 80 A secondary pancreatectomy for the remnant pancreas can be conducted without increasing morbidity and mortality, 81 so resection of the target area, rather than TP, has been preferable thus far. However, most recently, due to the improvements in postsurgical quality of life, TP combined with islet autotransplantation have been considered and actually indicated for FPC kindred with premalignant lesions. 80, 82 Further improvements are expected in the future.
6) Present outcome of surveillance
Several surveillance results have been reported from the Western FPC registries (Table 3) . 21, 28, 69, 76, [83] [84] [85] [86] [87] [88] [89] [90] About 2% to 18%
of the screened HRIs underwent surgery for suspected lesions. Roughly 30% to 40% of the resected cases were benign lesions that underwent unnecessary treatment, and only less than one fifth were borderline precursors and carcinoma in situ, or definitive targets of the surveillance. A small proportion of PC was resected at an early phase (T1N0M0), 90 and some PC cases were detected at the advanced unresectable stage. These outcomes are still apart from the goal of the surveillance. However, a recent study from Johns Hopkins demonstrated that 3-year survival rate of 10 PC cases diagnosed during surveillance was 85% and was significantly longer than those detected outside the surveillance (p=0.0009). Also 10 cases with PanIN3 or high-grade IPMN were all alive after surgery (4.1 to 14.7 year). These data suggested that current surveillance system prolonged the PCassociated survival in HRIs. 76 
CHEMOTHERAPY FOR FAMILIAL PANCREATIC CANCER WITH BRCA MUTATION
For unresectable PC, on the basis of current evidence, FOL-FIRINOX (fluorouracil, folic acid, irinotecan, and oxaliplatin) and gemcitabine-based regimens are standard choices of chemotherapy (median survival, 11 and 6-9 months, respectively). 91 However, in agreement with the response observed in HBOC patients, 92, 93 PC patients with germline BRCA1/2 mutation carriers respond well to platinum-based chemotherapy. Golan et al. 94 retrospectively compared overall survival (OS) of 43 patients with stage III-IV PC with BRCA mutation carriers in terms of their chemotherapy regimen-either platinum or nonplatinum. Superior OS was observed for patients treated with platinum chemotherapy (n=22) than with non-platinum (n=21) (22 months vs 9 months; p=0.039). A similar effect was experimentally confirmed. PC xenografts harvested from BRCA mutation carriers and implanted into nude mice showed sensitivity to both gemcitabine and cisplatin, meanwhile, xenografts from BRCA wild cases demonstrated sensitivity only to gemcitabine. 93 reported that a PARP inhibitor (PARPi) treatment induced a 22% response ratio with 4.6 months of progression-free survival in BRCA-mutant PC patients who had already showed progression resistant to the gemcitabine treatment. PARPi may be effective not only for breast and ovarian cancers 98 but also for PC cases with deficiency in the HR pathway; that is, as mentioned, in cases with either mutation of ATM, CHEK2, BRCA1, BRCA2, PALB2, or Rad51. This outcome is explained by a synthetic lethal theory, where apoptosis is induced by blocking both the single-and double-strand DNA break repair system. 99 Currently, data are lacking with respect to
PARPi use against FPC in causative mutation carriers and several phase II/III studies are now ongoing (https://clinicaltrials. gov). Future outcomes are expected.
CONCLUSIONS
Family history of PC and some genetic syndromes need to be taken into account when screening to detect early pancreatic cancer. So far, basic and clinical researches on the basis of family registries have accumulated much scientific information of FPC in the Western countries. However, at present, outcome of screening of HRIs is still not satisfactory. As life style, food, ethnicity, and medical system are different between the Western and Eastern countries, to detect early PC, we need to establish our own FPC registries and surveillance programs in the Asian countries.
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